STADA at a Glance
Key Facts
FAQs
Glossary
Print page
Send page
Bookmark page
STADA as homepage
Glossary
Index: ABCDEFGHIJKLMNOPQRSTUVWXYZ
| Active pharmaceutical ingredient | AMNOG |
| Approval | Audit |
| AVWG |
| BfArM | Bioequivalence |
| Biopharmaceuticals | Biosimilar |
| Bio-study | BMGS |
| Branded products |
| Centralized approval procedure | Commercial business |
| Commercial property rights | Co-payment |
| Cost bearer |
| Data exclusivity period | Decentralized European approval procedure |
| Dialysis | Dosage form |
| Dossier |
| Early entry | EMEA |
| Erythropoietin (abbreviation Epo) |
| FDA | Filgrastim |
| Freely-available drugs |
| Generics | GKV |
| GKV market | GKV-WSG |
| GMG | GMP |
| Health care products |
| Indication | Initial supplier |
| INN (International Non-proprietary Name) generics |
| Label |
| Manufacturing permit | Monoclonal Antibodies |
| MR procedure | Multiple ownership |
| Multisource products |
| NDA approval | Nephrology |
| Non-pharmacist ownership |
| Oncology | Orphan Drug |
| OTC market | OTX products |
| Parallel import | Patent |
| Pharmaceutical production | Pharmacovigilance |
| Pharmacy-only drugs | Prescription market |
| Prescription obligation | Protein |
| Reference pricing | Rituximab |
| Second supplier | Self-medication market |
| SPC | Subsequent approval |
| Trastuzumab | Therapeutics Advertising Act |
